CA-4948 is a small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) and FLT3 and is currently undergoing a Phase 1/2 study (NCT03328078) for its efficacy either alone as a monotherapy or in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies, including NHL, CLL, and Waldenstrom’s macroglobulinemia (WM). This evidence concerns the gene FLT3 and hematologic disorder.